Medtide Inc. (3880 HK) is a China-domiciled, peptide-focused contract research, development, and manufacturing organization (CRDMO). It provides full-cycle services from early-stage discovery to commercial-stage production of peptide APIs, with a strategic focus on the high-growth GLP-1 drug market. Medtide plans to list on the Hong Kong Stock Exchange on June 30, 2025, offering 16.8 million shares priced between HKD 28.40 and HKD 30.60. The company expects to raise up to HKD 514.08 million (USD 65.49 million). According to reports, the proceeds will be used primarily to expand manufacturing capacity and enhance R&D capabilities, with the remainder allocated to working capital and general corporate purposes.